Special care needs to be taken when considering radiotherapy for patients during pregnancy. There are no hard and fast rules, but the patient, family members, treating oncologist and other team members should carefully discuss the decisions made.
Yes, but important factors must be considered. The most important considerations, as suggested by the ICRP, include:
INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION, Pregnancy and Medical Radiation, ICRP Publication 84, Pergamon Press, Oxford and New York (2000).
By following documented expert recommendations on foetal dose reduction.
The first consideration is if the treatment can be postponed until the foetus is at a later gestation age. If the decision is made that radiotherapy is necessary, it is important to calculate the dose to the foetus before the treatment is given. When external radiotherapy is used for treatment of tumours at some distance from the foetus, a very important factor in foetal dose is the distance from the edge of the radiation field. The American Association of Physicists in Medicine (AAPM) recommends that the following points be considered:
STOVALL, M., BLACKWELL, C.R., CUNDIFF, J., NOVACK, D.H., PALTA, J.R., WAGNER, L.K., WEBSTER, E.W., SHALEK, R.J., Foetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36, Med. Phys. 22 1 (1995) 63-82.
Unfortunately, it is likely that pregnancy will be terminated.
Carcinoma of the cervix is the most common malignancy associated with pregnancy. Cervical cancer complicates about one out of 1250 to 2200 pregnancies. This rate, however, varies significantly by country. Cervical cancer is often treated by surgery/radiotherapy (external beam radiotherapy and brachytherapy) and the absorbed doses required with both forms of radiotherapy will cause termination of pregnancy. If the tumour is infiltrative and is diagnosed late in pregnancy, an alternative is to delay treatment until the baby can be safely delivered. Regardless of protective measures, radiotherapy involving the pelvis of a pregnant female almost always results in severe consequences for the foetus, most likely foetal death.
The wait can be substantial and needs to be discussed with her radiation oncologist.
Most radiation oncologists advise their patients not to become pregnant for 1-2 years after completion of therapy. This is not primarily related to concerns about potential radiation effects, but rather to considerations about the risk of relapse of the tumour that would require more radiation, surgery, or chemotherapy.
There is no likely effect.
Radiation exposure occurred before conception, so any effect on the offspring would be classed as genetic effect. No data from humans show any statistically significant genetic effect in any population, even the Japanese atomic bomb survivors. All estimates of genetic radiation risk come from studies of rodents, which show that males are far more sensitive than females. However, it is not easy to extrapolate this data to humans. There is very low risk of any effect on the unborn child. The World Health Organization estimates that the worldwide incidence of inherited disease (ranging from severe to as trivial as an inconspicuous birthmark) is about 10%. In the unfortunate event that the child is born with any genetic abnormality, it is extremely unlikely that it would be related to the earlier radiation exposure.
There is no danger involved.
Prostate brachytherapy can be performed with permanent implantation of radioactive 103Pd or 125I seeds, and the patient is discharged from hospital with these in place. The short range of the emissions from these radionuclides is the reason that the patient can be discharged and is the reason that these patients pose no danger to pregnant family members. Other brachytherapy patients are kept in the hospital until the sources are removed. While these patients can occasionally be a source of radiation to a pregnant family member, the potential dose to the foetus is very low, irrespective of the type of brachytherapy.